BRAF and colorectal carcinoma: In a pivotal, single-arm study that included 43 patients with BRAF-V600E metastatic CRC treated with the adjunct of a MEK inhibitor (Trametinib), the results showed improved response rates compared with BRAF inhibition alone [95].